Uncategorized

Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the appointment of Bernd Schmidt, a senior leader with extensive experience in Chemistry, Manufacturing and Controls, as Chief Technical Officer, effective as of today.

Ascentage Pharma announced that it has released the results of lisaftoclax, one of the company’s key drug candidates, in patients with treatment-naïve or relapsed/refractory acute myeloid leukemia or other myeloid neoplasms, in a Poster Presentation at the 65th American Society of Hematology Annual Meeting, taking place in San Diego, CA, the United States.

Bristol Myers Squibb announced updated results from three key programs within its broad multiple myeloma research pipeline, highlighting its diverse targets and molecular approaches to address unique patient needs within the disease.

Johnson & Johnson announced new patient-reported outcomes from the Phase 3 CARTITUDE-4 study of CARVYKTI® demonstrated clinically meaningful improvements in health-related quality of life and meaningful reductions in disease-specific symptoms according to multiple PRO measures in the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma who received one to three prior lines of

Bristol Myers Squibb and 2seventy bio, Inc. announced results from the preplanned final progression-free survival analysis of KarMMa-3, the pivotal Phase 3, open-label, global, randomized controlled study evaluating Abecma compared with standard combination regimens in adults with relapsed and refractory multiple myeloma after two to four prior lines of therapy.

During the ESMO Immuno-Oncology Congress 2023 held in Geneva, Switzerland, from December 6th to 8th, Qilu Pharmaceutical presented the latest results of the Phase I clinical trial for QLS31905 in patients with advanced solid tumors through a poster presentation.

Johnson & Johnson announced an analysis from the Phase 1/2 MonumenTAL-1 study of TALVEY™ in patients with relapsed or refractory multiple myeloma showed that patients treated with TALVEY™ were subsequently treated effectively with several classes of therapy, including anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy as well as BCMA and anti-Fc receptor-like protein 5

El carcinoma hepatocelular (CHC) es una neoplasia maligna importante en todo el mundo

Prácticas esenciales para hospitales de cuidados intensivos en el uso de catéteres uretrales y opciones para la administración de urocultivos

The Indiana-based pharma shed shares after a study published Monday in JAMA showed “substantial” weight gain after patients discontinued treatment with the GLP-1 receptor agonist.